ClinicalTrials.gg
Active, not recruitingNCT06613880Updated Nov 4, 2026

Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia

A Phase 2 interventional study of standard IST combined with Romiplostim N01 in Aplastic Anemia and TPO Receptor Agonists, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Active, not recruiting at 1 site in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

How we know

Updated Nov 4, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China — 16 open to participants now, 18 under way, none of them phase 3. Anemia, Aplastic · Institute of Hematology & Blood Diseases Hospital, China.

Enrollment
9th of 25
48 · median 40
Started
2024
with 2 others
Phase 2
14 of 31
5 open now
Primary completion
2025-09
later than 3 of 17 live
Registered
16th of 31
by date

Among the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China, this one is the 9th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2024, is one of 14 in phase 2, reaches primary completion later than 3 of the 17 other live ones, and was the 16th registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

16 of the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

This prospective, single center, single-arm study aims to evaluate the efficacy and safety of anti-human T lymphocyte porcine immunoglobulin (p-ALG) in combination with cyclosporine and Romiplostim in treating severe aplastic anemia (SAA). It will include 48 patients with newly diagnosed SAA.

03

Conditions studied

  • Aplastic Anemia
  • TPO Receptor Agonists

Browse trials for

Keywords

  • Severe aplastic anemia
  • Romiplostim N01
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 12 years
  • Diagnosis of severe or very severe aplastic anemia
  • Patients are unconditionally or unacceptable undergoing hematopoietic stem cell transplantation
  • performance status ≤2
  • Willing and able to comply with the requirements for this study and written .

Exclusion criteria

Exclusion Criteria:

  • Received > 4 weeks of TPO-RA drug before treatment
  • Received > 4 weeks of therapy before treatment
  • History of thromboembolic disease
  • Intolerance to Romiplostim N01 or cyclosporine
  • Allergy to ALG
  • Presence of uncontrolled active infection
  • Presence of uncontrolled hypertension (≥140/90mmHg), diabetes mellitus (fasting blood glucose≥ 7.0 mmol/L or random blood glucose ≥ 11.1 mmol/L)
  • Abnormal liver and kidney function: (AST) or Alanine Transaminase (ALT) > 3 , creatinine ≥ 2.5 ULN
  • History of chemoradiotherapy for malignant solid tumors
  • History of other systemic serious illnesses
  • Females who are pregnant/lactating or need pregnancy
  • Patients considered to be ineligible for the study by the investigator for reasons other than the above
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    p-ALG+Romiplostim N01+CsA

    The maximum screening period was 4 weeks, and after entering the treatment period, the patients were treated with p-ALG combined with cyclosporine and Romiplostim N01. Symptomatic leukocyte elevation, blood transfusion support, and anti-infective therapy are allowed during this period, according to the patient's blood routine. If a patient has a serious adverse event during treatment, it will be treated according to the criteria for suspension and recovery.

    Drug: standard IST combined with Romiplostim N01

Interventions

  • Drugstandard IST combined with Romiplostim N01

    Romiplostim N01 is a class of TPO receptor agonists. Its TPO peptide can bind to TPO receptors on megakaryocyte precursors in the bone marrow and activate them, triggering a series of intracellular signalling pathways, including JAK2/STAT5, PI3K/Akt, MEK/ERK, and p38, which ultimately lead to gene transcription and increased megakaryocyte proliferation and differentiation.

06

What researchers measure

Primary outcomes

  1. Overall response rate

    Percentage of patients with hematological response, including complete response (CR) or partial response (PR). Hematological response is evaluated by hemoglobin (Hb), platelet count (PLT) and absolute neutrophil count (ANC).

    Time frame: Within 27 weeks post treatment

Secondary outcomes

  1. Overall response rate

    Percentage of patients with hematological response, including complete response (CR) or partial response (PR). Hematological response is evaluated by hemoglobin (Hb), platelet count (PLT) and absolute neutrophil count (ANC).

    Time frame: Within 3 months post treatment

  2. Time to hematological response

    Duration time was calculated from enrollment to achieve hematological response.

    Time frame: Within 27 weeks post treatment

  3. Incidence of adverse events

    Use Common Terminology Criteria for Adverse Events (CTCAE) Version 5 to assess the adverse event

    Time frame: Within 27 weeks post treatment

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Sep 2025, 11 months.

Of 51 non-industry phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 111. This study's 11 months is below that.

Counting every sponsor, half of 59 studies reached it within 76 months; a quarter within 39 and three quarters within 104.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Jan 2026 → Sep 2025 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Sep 26, 2024
StartActual
Oct 24, 2024
Primary completionActual
Sep 26, 2025was Jan 2026
CompletionEst.
Sep 30, 2027was Sep 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 4, 2026
Sites
1 site added, 1 site removed
Show site
  • Regenerative Medicine Center and Red Blood Cell Disorders Center · Tianjin, China
Show 1 removed
  • Regenerative Medicine Center and Red Blood Cell Disorders Center · Tianjin, China
Nov 4, 2026
Primary completion
Jan 31, 2026→Sep 26, 2025 (actual)
Nov 4, 2026
Study completion
Sep 30, 2026→Sep 30, 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Regenerative Medicine Center and Red Blood Cell Disorders Center · Tianjin, China
    Show 1 removed
    • Regenerative Medicine Center and Red Blood Cell Disorders Center · Tianjin, China
    Primary completion Jan 31, 2026→Sep 26, 2025 (now actual)
    Study completion Sep 30, 2026→Sep 30, 2027
    + 4 other changes: verification date, responsible party, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06613880
Responsible party
Jun Shi (Director of the Red Blood Cell Disorders Center & Director of the Regenerative Medicine Clinic, Institute of Hematology & Blood Diseases Hospital, China) — Principal investigator
First posted
Sep 26, 2024
Start date
Oct 24, 2024
Primary completion
Sep 26, 2025
Completion
Sep 30, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Jun Shi, PhD
principal investigator · Institute of Hematology & Blood Diseases Hospital, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion